Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5469907 | 1.00 | HSD17B10 (0.61) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL5423413 | 1.00 | HSD17B10 (0.61) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL13804206 | 0.95 | HSD17B10 (0.56) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL12427648 | 0.95 | HSD17B10 (0.56) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL13804123 | 0.95 | HSD17B10 (0.56) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL31048407 | 0.93 | HSD17B10 (0.55) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL7286305 | 0.90 | HSD17B10 (0.61) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL19414808 | 0.90 | HSD17B10 (0.61) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL895773 | 0.90 | HSD17B10 (0.61) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 | |
| SCHEMBL14000638 | 0.89 | HSD17B10 (0.49) | HSD17B10NPC1SMN1; SMN2LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313553-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTL GMBH CORP (DE) | 2025-10-09 | — | — | US | disclosed |
| US-20250136582-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | 1200 PHARMA LLC (US) | 2025-05-01 | — | — | US | disclosed |
| CN-119156383-A | Selective KRAS G12C inhibitors and uses thereof | 1200药业有限责任公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-119013272-A | Cyclic 2-amino-3-cyanothiophenes and derivatives thereof for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4441050-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2024-10-09 | — | — | EP | disclosed |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | ELI LILLY AND COMPANY | 2024-07-11 | — | — | US | disclosed |
| CN-112812128-B | Macrocyclic compounds as ALK and ROS modulators | 正大天晴药业集团股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| CN-111925360-B | 1-heterocyclylisochromanyl compounds and analogs for the treatment of CNS disorders | 赛诺维信制药公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CEREVANCE LTD (GB) | 2024-02-22 | — | — | US | disclosed |
| US-7358378-B2 | Processes for the preparation of paclitaxel | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20080051407-A1 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | PHARMA MAR, S.A., A MADRID SPAIN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20070276017-A1 | Thiadiazoline Derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2007-11-29 | — | — | US | disclosed |
| US-7173024-B2 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2007-02-06 | — | — | US | disclosed |
| WO-2006127550-A1 | PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | ORION CORPORATION (FI) | 2005-01-27 | — | — | US | disclosed |
| EP-1401810-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003004468-A1 | COMPOUNDS HAVING PROLYL OLIGOPEPTIDASE INHIBITORY ACTIVITY, METHODS FOR THEIR PREPARATION AND THEIR USE | ORION CORPORATION (FI) | 2003-01-16 | — | — | WO | disclosed |
| CN-1348442-A | Novel sulfonamide compounds and uses thereof | MERCK & CO INC (US) | 2002-05-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136582-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | HSD17B10 3478/4885NPC1 1597/4885SMN1; SMN2 1670/4885 |
| US-20250313553-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | KRAS, NRAS, TP53 | HSD17B10 4874/4885NPC1 3943/4885SMN1; SMN2 3654/4885 |
| US-20240059677-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS NICOTINIC ACETYLCHOLINESTERASE RECEPTOR ALPHA 6 MODULATOR | CHRNA6, CHRM2, CHRNA1 | HSD17B10 2585/4885NPC1 2248/4885SMN1; SMN2 1414/4885 |
| US-20070276017-A1 | Thiadiazoline Derivative | BRD7, NR3C2, NR5A2 | HSD17B10 903/4885NPC1 3452/4885SMN1; SMN2 4003/4885 |
| US-20050020677-A1 | Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use | DNPEP, PREP, ANPEP | HSD17B10 1513/4885NPC1 754/4885SMN1; SMN2 2511/4885 |
| US-20240228511-A1 | SUBSTITUTED FUSED AZINES AS KRAS G12D INHIBITORS | KRAS, NRAS, TP53 | HSD17B10 4403/4885NPC1 2826/4885SMN1; SMN2 3062/4885 |
| US-20080051407-A1 | These compounds lack a 1,4-bridging group as found in the ecteinascidins; and, have at the C-1 position a substituent selected from an amino or hydroxy group, optionally protected or derivatized; anticarcinogenic agents | FN1, RCN1, ERCC4 | HSD17B10 1242/4885NPC1 4435/4885SMN1; SMN2 3230/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | HSD17B10 3889/4885NPC1 1409/4885SMN1; SMN2 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.